What is Novavax's market cap?

Novavax (NVAX) has a market capitalization of $1.2B and trades on NASDAQ.

What is Novavax's revenue and profitability?

Novavax generated $596.3M in trailing twelve-month revenue with a net loss of $87.8M, representing a net margin of -14.7%. Gross margin stands at 85.0%, with free cash flow of -$389.7M. These figures are based on the Q1 2026 filing.

Who are Novavax's competitors?

Novavax's key competitors include Moderna, Inc., Invivyd, Inc. Common Stock, GeoVax Labs, Inc. New, and others. These companies compete in similar markets and product categories.

Who does Novavax partner with?

Novavax's notable partners include Sanofi, Pfizer Inc., Serum Institute of India, and others.

Where is Novavax headquartered?

Novavax is headquartered in United States of America and employs approximately 1,992 people. It has been publicly traded since 1995.

Novavax

NVAX

Novavax is a biotechnology company that develops and commercializes innovative vaccines to address serious infectious diseases.

Market cap

$1.23B+11.0%

Revenue$596.3M-52.5%

Net income-$87.8M-118%

Free cash flow-$389.7M-288%

EPS (diluted)-$0.64-124%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$139.5MBeat by $59.7M EPS-$0.06Beat by $0.19

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$52.1M

EPS estimate-$0.40

Financials

Q1 2026

Income statement

See full

Revenue$139.5M-79.1%

Gross profit$108.8M-83.3%

Operating income-$15.4M-103%

Net income-$9.5M-102%

EPS (diluted)-$0.06-102%

Balance sheet

See full

Cash & equivalents$228.4M-13.3%

Total debt$295.1M+404%

Total equity-$144.8M-91.4%

Total assets$1.0B-19.3%

Cash flow

See full

Operating cash flow-$32.4M+82.5%

CapEx$1.3M-20.4%

Free cash flow-$33.7M+82.0%

Valuation & ratios

Valuation

See full

Market cap$1.23B+11.0%

Enterprise value$1.3B+32.0%

P/S2.1×+1.0×

Profitability

See full

Gross margin85%-2.5pp

Operating margin-13.1%-45.9pp

Net margin-14.7%-52.9pp

Returns & leverage

See full

Current ratio2.5×+0.4×

Segments

By geography

See full

Rest of the world$23.3M-46.5%

Europe$20.1M+149%

By segment

See full

Reportable Segment$139.5M-79.1%

By product

See full

Royalties$3.5M—

Competitors

By market cap

Merck & Co.$322.95B+53.0%

Moderna$22.1B+68.3%

Vaxcyte, Inc.$8.0B+73.2%

Novavax$1.2B+4.5%

Invivyd, Inc.$179.7M+78.9%

NNV

NanoViricides$35.4M+29.5%

Soligenix, Inc.$5.4M+28.4%

GeoVax Labs$4.0M-78.7%

By revenue growth

Merck & Co.+2.9%

Moderna-30.0%

Novavax-52.5%

By net margin

Merck & Co.13.59%-13.7pp

Novavax-14.73%-52.9pp

Moderna-143.55%-37.9pp

Profile

Novavax is a biotechnology company that develops and commercializes innovative vaccines to address serious infectious diseases. The company leverages a proprietary recombinant protein-based nanoparticle technology and its Matrix-M™ adjuvant to induce potent and durable immune responses. Its business strategy focuses on maximizing the value of its technology platform through strategic licensing and global partnerships.

Competitive position

A specialized vaccine developer known for its unique protein-based nanoparticle platform and potent Matrix-M adjuvant, often acting as a technology provider to larger pharmaceutical incumbents.

GeographiesUnited States, European Union, Australia, Global

Customer segmentsGovernments, Healthcare Providers, Pharmaceutical Companies

Business modelIP Licensing, Research and Development, Product Sales

SuppliersBaculovirus Sf-9 insect cell-expression systems, Raw material suppliers for adjuvant production, Contract manufacturing organizations (CMOs)

CustomersGovernment health agencies, Gavi, the Vaccine Alliance, Retail pharmacies, Hospitals and clinics

CountryUnited States of America

Listed1995

Employees2.0K

CEOJohn Charles Jacobs

SectorHealthcare

IndustryBiotechnology

Websitenovavax.com

FilingsSEC EDGAR

Ask your AI about Novavax.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Novavax's market cap?: Novavax (NVAX) has a market capitalization of $1.2B and trades on NASDAQ.
What is Novavax's revenue and profitability?: Novavax generated $596.3M in trailing twelve-month revenue with a net loss of $87.8M, representing a net margin of -14.7%. Gross margin stands at 85.0%, with free cash flow of -$389.7M. These figures are based on the Q1 2026 filing.
Who are Novavax's competitors?: Novavax's key competitors include Moderna, Inc., Invivyd, Inc. Common Stock, GeoVax Labs, Inc. New, and others. These companies compete in similar markets and product categories.
Who does Novavax partner with?: Novavax's notable partners include Sanofi, Pfizer Inc., Serum Institute of India, and others.
Where is Novavax headquartered?: Novavax is headquartered in United States of America and employs approximately 1,992 people. It has been publicly traded since 1995.